>>Signaling Pathways>> Microbiology & Virology>> Reverse Transcriptase>>Islatravir (MK-8591)

Islatravir (MK-8591) (Synonyms: 4’Ed2FA, 4′-ethynyl-2-fluoro-2′-Deoxyadenosine, EFDA, MK-8591)

Catalog No.GC32306

이슬라트라비르(MK-8591)(MK-8591)는 뉴클레오시드 역전사효소 억제제로 작용하는 강력한 항HIV-1 제제로, HIV-1(WT), HIV-1에 대해 EC50이 0.068 nM, 3.1 nM 및 0.15 nM입니다. 1(M184V), HIV-1(MDR).

Products are for research use only. Not for human use. We do not sell to patients.

Islatravir (MK-8591) Chemical Structure

Cas No.: 865363-93-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$413.00
재고 있음
5mg
US$378.00
재고 있음
10mg
US$612.00
재고 있음
25mg
US$1,350.00
재고 있음
50mg
US$2,250.00
재고 있음
100mg
US$3,713.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Islatravir (MK-8591) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC50s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively.

Islatravir (MK-8591) (4'Ed2FA) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC50s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively[1].

[1]. Ohrui H, et al. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec. 2006;6(3):133-43.

리뷰

Review for Islatravir (MK-8591)

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Islatravir (MK-8591)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.